All You Need to Know About Ginkgo Bioworks (DNA) Rating …

Dec 17, 2024 · Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CouponFollow Extension

$40.00
OFF

Analysts Offer Insights On Healthcare Companies: Ginkgo Bioworks ...

4 days from now

Aug 20, 2024 · Ginkgo Bioworks Holdings (DNA) Morgan Stanley analyst Tejas Savant maintained a Hold rating on Ginkgo Bioworks Holdings today and set a price target of $40.00 . …

businessinsider.com

50%
OFF

Rating History - DNA - NYSE - Weiss Ratings

4 days from now

Ginkgo Bioworks Holdings, Inc. DNA $0.8421-$0.049-5.50%. Recommendation

weissratings.com

21%
OFF

3 Things About Ginkgo Bioworks That Smart Investors Know

4 days from now

Apr 1, 2022 · With its shares popping by more than 21% in a day in the aftermath of its latest earnings report, Ginkgo Bioworks (DNA-8.23%) is a hot biotech company that's ripe for …

fool.com

$9
OFF

Ginkgo Bioworks Eligible For $9.4M In Partnership For Bioelectronic ...

4 days from now

Dec 17, 2024 · Ginkgo Bioworks announced a subcontract of up to $9.4M awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at …

businessinsider.com

$9
OFF

Ginkgo Bioworks Awarded $9.4 Million In Partnership With …

4 days from now

BOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to …

morningstar.com

FAQs about All You Need to Know About Ginkgo Bioworks (DNA) Rating … Coupon?

Should you buy Ginkgo Bioworks (DNA) stock?

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. ...

Should you buy G inkgo Bioworks holdings (DNA)?

G inkgo Bioworks Holdings, Inc. (DNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. ...

Is Ginkgo Bioworks a good biotech?

It needs to work within the constraints imposed by these three issues. Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (DNA -2.25%) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. ...

Should you buy Ginkgo Bioworks holdings (Goparaju)?

According to TipRanks, Goparaju has an average return of -31.1% and a 17.39% success rate on recommended stocks. Ginkgo Bioworks Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $2.58, implying an 118.64% upside from current levels. ...

Will Ginkgo Bioworks (Ginkgo) move higher in the near term?

The upgrade of Ginkgo Bioworks to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. To read this article on Zacks.com click here. ...

Is Ginkgo Bioworks (DNA) oversold?

The two companies have previously collaborated on next-generation seed technology. Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. ...